Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CDC42 | P60953 | 1/20 | 0.45 |
| ▸ | RAC1 | P63000 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1473746 | 0.88 | MAPT (0.65) | CYP3A4MAPTMEN1PPARGKMT2A | |
| SCHEMBL13100433 | 0.84 | MEN1 (0.54) | CYP3A4MAPTMEN1PPARGKMT2A | |
| SCHEMBL30511127 | 0.81 | HIF1A (0.79) | CYP3A4MAPTMEN1PPARGKMT2A | |
| SCHEMBL23523355 | 0.81 | HIF1A (0.79) | CYP3A4MAPTMEN1PPARGKMT2A | |
| SCHEMBL23564661 | 0.81 | HIF1A (0.79) | CYP3A4MAPTMEN1PPARGKMT2A | |
| SCHEMBL12255051 | 0.80 | MEN1 (0.56) | CYP3A4MAPTMEN1PPARGKMT2A | |
| SCHEMBL14156990 | 0.79 | HIF1A (0.57) | CYP3A4MAPTMEN1PPARGKMT2A | |
| SCHEMBL13090328 | 0.78 | CYP3A4 (0.74) | CYP3A4MAPTMEN1PPARGKMT2A | |
| SCHEMBL13090332 | 0.77 | MEN1 (0.59) | CYP3A4MAPTMEN1PPARGKMT2A | |
| SCHEMBL16201608 | 0.77 | MAPT (0.59) | CYP3A4MAPTMEN1PPARGKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1743881-B1 | Phenyl-benzyl-ketones | RUANE MICHAEL (AU) | 2010-12-22 | — | — | EP | disclosed |
| US-20100273891-A1 | ISOFLAVONE METABOLITES | Ruane, Michael (AU) | 2010-10-28 | — | — | US | disclosed |
| US-20100273891-A1 | ISOFLAVONE METABOLITES | Ruane, Michael (AU) | 2010-10-28 | — | — | US | disclosed |
| US-7799955-B2 | Isoflavone metabolites | Ruane, Michael (AU) | 2010-09-21 | — | — | US | disclosed |
| US-7799955-B2 | Isoflavone metabolites | Ruane, Michael (AU) | 2010-09-21 | — | — | US | disclosed |
| US-20090209655-A1 | ISOFLAVONE METABOLITES | G. J. CONSULTANTS PTY. LTD. (AU) | 2009-08-20 | — | — | US | disclosed |
| US-20090209655-A1 | ISOFLAVONE METABOLITES | G. J. CONSULTANTS PTY. LTD. (AU) | 2009-08-20 | — | — | US | disclosed |
| US-20080125481-A1 | ISOFLAVONE METABOLITES | JOANNOU GEORGE EUSTACE | 2008-05-29 | — | — | US | disclosed |
| US-20080125481-A1 | ISOFLAVONE METABOLITES | JOANNOU GEORGE EUSTACE | 2008-05-29 | — | — | US | disclosed |
| EP-1743881-A1 | Phenyl-benzyl-ketones | G.J. Consultants Pty Ltd (AU) | 2007-01-17 | — | — | EP | disclosed |
| EP-1189897-B1 | ISOFLAVONE METABOLITES | G J CONSULTANTS PTY LTD (AU) | 2006-10-18 | — | — | EP | disclosed |
| US-7056952-B1 | for example, 3'-hydroxy-dihydrodaidzein, 5-hydroxy-O-demethylangolesin; for treating hormone dependent conditions and other diseases and disorders; anticarcinogenic agents | G.J. CONSULTANTS PTY. LTD. (AU) | 2006-06-06 | — | — | US | disclosed |
| US-20050222248-A1 | Isoflavone metabolites | JOANNOU GEORGE E | 2005-10-06 | — | — | US | disclosed |
| EP-1189897-A1 | ISOFLAVONE METABOLITES | G.J. Consultants Pty Ltd (AU) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000066576-A1 | ISOFLAVONE METABOLITES | G.J. CONSULTANTS PTY LTD (AU) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222248-A1 | Isoflavone metabolites | CYP19A1, ESR1, CYP21A2 | CYP3A4 54/4885MAPT 4750/4885MEN1 338/4885 |
| US-20100273891-A1 | ISOFLAVONE METABOLITES | CYP19A1, ESR1, CYP21A2 | CYP3A4 57/4885MAPT 4713/4885MEN1 351/4885 |
| US-20090209655-A1 | ISOFLAVONE METABOLITES | CYP19A1, ESR1, CYP21A2 | CYP3A4 57/4885MAPT 4713/4885MEN1 351/4885 |
| US-20080125481-A1 | ISOFLAVONE METABOLITES | CYP19A1, ESR1, CYP21A2 | CYP3A4 57/4885MAPT 4713/4885MEN1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.